Global /China /Healthcare /Drug Manufacturers - General /300497

Jiangxi Fushine Pharmaceutical Co., Ltd.

300497

• SHE: 300497 • Delayed

19.32CNY -2.6%

2.85 USD

As of 17 June 2026, Jiangxi Fushine Pharmaceutical Co., Ltd. has a market cap of $1.58B USD, ranking #8226 globally and #2112 in China. It ranks #691 in the Healthcare sector, and #266 in the Drug Manufacturers - General industry.

Global Rank

8226

Country Rank

2112

Sector Rank

691

Industry Rank

266

Key Stats

Market Cap

$1.58BUSD

10.68B CNY

Enterprise Value

$1.75BUSD

11.85B CNY

Revenue (TTM)

$193.72MUSD

1.31B CNY

EBITDA (TTM)

$39.62MUSD

268.15M CNY

Net Income (TTM)

$581.75KUSD

3.93M CNY

EBITDA Margin

20%

Profit Margin

0.3%

PE Ratio

2717.1

Forward PE

15.4

PS Ratio

8.2

PB Ratio

4.7

EV/EBITDA

44.2

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jian Hua Bao open_in_new

Employees

1,774

Founded

2002

Website

fushine.cn open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.6%	7.3%	1.2%	24%	92%	28%	129%	49%	66%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	300497 江西富祥药业股份有限公司 Class A ISIN: CNE1000024Z7 Shares Out.: Shares Outstanding: 538.649M¹ Shares Float: 490.894M² TV: TradingView: SZSE: 300497 SA: Stock Analysis: SHE: 300497 YF: Yahoo Finance: 300497.SZ GF: Google Finance: SHE: 300497 BA: Barron's: 300497 MS: Morningstar: XSHE: 300497	19.32 CNY	TV: TradingView: SZSE: 300497 SA: Stock Analysis: SHE: 300497 YF: Yahoo Finance: 300497.SZ GF: Google Finance: SHE: 300497 BA: Barron's: 300497 MS: Morningstar: XSHE: 300497

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Jiangxi Fushine Pharmaceutical Co., Ltd.

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancroid. It also provides lithium-ion battery electrolyte additives; and microbial protein, amino acid water-soluble fertilizer, and other bio-fermentation products. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. Jiangxi Fushine Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Jingdezhen, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$54.0B 364.89B CNY 3K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.78B 336.36B CNY 3K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.53B 223.48B HKD 2K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.81B 147.32B HKD 1K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.56B 111.89B CNY 948%	-	China
Akeso, Inc. SHEK: 9926	$16.02B 125.46B HKD 913%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 48K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 35K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 23K%	97.4	United States
Roche Holding AG SIX: RO	$323.08B 256.25B CHF 20K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.3B 215.59B GBP 18K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$275.99B 218.9B CHF 17K%	20.5	Switzerland

chevron_leftBack